Another clinical trial is aimed at targeting ATM deficient advanced lung adenocarcinomas as well as high grade ovarian cancers that harbor BRCA1/2 mutations using a combination of AZD6738 and carboplatin (NCT02264678) [55]. This evidence concerns the gene ATM and lung adenocarcinoma.